|[January 14, 2013]
Research and Markets: EpiCast Report: Colorectal Cancer Epidemiology Forecast to 2022
DUBLIN --(Business Wire)--
Research and Markets (http://www.researchandmarkets.com/research/77bgc8/epicast_report)
has announced the addition of GlobalData's new report "EpiCast Report:
Colorectal Cancer Epidemiology Forecast to 2022" to their offering.
Colorectal cancer is the third most common cancer in men and second most
common cancer in women. Epidemiologists expect the number of incident
and prevalent cases of colorectal cancer in the US, Germany, Italy,
Spain, the UK, Japan, India, and China to increase during the forecast
period. Incident and prevalent cases in France is expected to stay
The number of total incident cases for all markets combined will
increase from 1.23 million cases in 2012 to 1.75 million cases in 2022
at the rate of 4.22% per year. China has the larest number of incident
cases in 2012 (645,057 cases), in 2022 (1.05 million cases), as well as
the highest growth (6.32% per year) of all nine markets.
The markets vary in age distribution of incident cases, gender gap,
cancer stage at diagnosis, and screening programs. However, resection
treatment is universally common where around 70-90% of colorectal cases
in each market receive resection treatment.
- Provides an overview of risk factors and global trends for colorectal
cancer in the seven major markets (the US, France, Germany, Italy,
Spain, the UK, and Japan) along with emerging markets India and China.
- Includes a 10-year epidemiological forecast of incident and five-year
prevalent cases of colorectal cancer.
- Describes patient population through segmentation by gender, age,
stage at diagnosis (TNM/AJCC I-IV), and resection treatment status.
Reasons to buy
- Develop business strategies by understanding the trends that shape and
drive the global colorectal cancer market.
- Quantify patient populations in the global colorectal cancer market to
improve product development, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups,
gender, stages of diagnosis, and resection-treated populations that
present the best opportunities for colorectal cancer therapeutics in the
nine major markets.
For more information visit http://www.researchandmarkets.com/research/77bgc8/epicast_report
Source (News - Alert): GlobalData
[ Back To Technology News's Homepage ]